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Abstract
Background: Pentraxin-3 (PTX-3) is an acute-phase protein involved in inflammatory and infectious processes. This study
assesses its diagnostic and prognostic value in patients with sepsis or septic shock in a medical intensive care unit (ICU).
Methods: The study includes 213 ICU patients with clinical criteria of sepsis and septic shock. 77 donors served as
controls. Plasma levels of PTX-3, procalcitonin (PCT) and interleukin-6 were measured on day 1, 3 and 8.
Results: PTX-3 correlated with higher lactate levels as well as with APACHE II and SOFA scores (p = 0.0001). PTX-3 levels
of patients with sepsis or septic shock were consistently significantly higher than in the control group (p ≤ 0.001). Plasma
levels were able to discriminate sepsis and septic shock significantly on day 1, 3 and 8 (range of AUC 0.73–0.92,
p = 0.0001). Uniform cut-off levels were defined at ≥5 ng/ml for at least sepsis, ≥9 ng/ml for septic shock (p = 0.0001).
Conclusion: PTX-3 reveals diagnostic value for sepsis and septic shock during the first week of intensive care treatment,
comparable to interleukin-6 according to latest Sepsis-3 definitions.
Trial registration: NCT01535534. Registered 14.02.2012
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Background
Sepsis is a widely common clinical syndrome, caused by
a systemic infection and accompanied by consecutive
organ failure often leading to a lethal outcome [1–3].
Hence, the early diagnosis and identification of sepsis
patients is essential, as early evidence-based treatment
and therapeutic interventions are likely to improve
survival and decrease in-hospital mortality rates [2, 4–8].
Both the widely used C reactive protein (CRP) and [9]
procalcitonin (PCT) are inconsistent concerning
diagnostic capacity [10]. Accordingly, the evaluation of
new diagnostic biomarkers discriminating patients with
sepsis or septic shock in an early stage is essential, as
mortality rates of specifically septic shock are still
unacceptably high despite the developments of modern
intensive care medicine.
Pentraxin-3 (PTX-3) is an acute phase protein repre-
senting the long pentraxin subfamily [11–13]. Production
of PTX-3 is strongly induced by cytokines like interleukin-
1, tumor necrosis factor α (TNF-α) and by toll-like
receptor (TLR) agonists, but not by interleukin 6 (IL-6) or
interferons [11, 12]. PTX-3 is expressed in various cells,
like dendritic cells, monocytes, endothelial cells or neutro-
phils during inflammatory processes [13–15]. Several
studies found increased PTX-3 expression due to various
specific infectious agents such as aspergillus fumigatus,
Staphylococcus aureus, pseudomonas aeruginosa, Klebsi-
ella pneumoniae, E. coli, neisseria meningitides, and
multiple viruses [16–21]. PTX-3 appears to reveal signifi-
cant potential as a novel early diagnostic and prognostic
biomarker in infectious disorders and septic patients as
analyzed in former studies [13–16, 22, 23]. However, the
previous studies showed inconsistent study cohorts of
different size and composition as well as different follow-
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up periods, not enabling an expressive conclusion consid-
ering the role of PTX-3 in these patients [23–31].
Additionally, there are currently no biomarker studies
evaluating the diagnostic value of PTX-3 according to
the latest Sepsis-3 definitions [3]. Therefore, this study
applies these definitions and aims to investigate the diag-
nostic value of PTX-3 in patients with sepsis and septic
shock during the first week of intensive care treatment.
Methods
Study patients, design and data collection
The Mannheim Sepsis Study (MaSep, clinicaltrials.gov
identifier: NCT01535534) was conducted as a mono-
centric prospective controlled study at the University
Medical Centre Mannheim (UMM), Germany. Patient
enrolment started in October 2011. The study was car-
ried out according to the principles of the declaration of
Helsinki and was approved by the medical ethics com-
mission II of the Faculty of Medicine Mannheim, Univer-
sity of Heidelberg, Germany. Written informed consent
was obtained from each participating patient or their
legal representatives. The study was designed to re-
flect a representative cohort of patients found at an
internal intensive care unit (ICU) with a minimum
age of 18 years and proven criteria of sepsis or septic
shock [32]. Main exclusion criteria were any trau-
matic or postoperative cause of sepsis development.
We enrolled a total of 30 healthy volunteers in
addition to 30 hospitalized patients being treated for
different medical conditions without any evidence of
infection (normal CRP, WBC, body temperature) serv-
ing as controls.
At the end of each hospital treatment, two study
physicians independently reviewed all available clinical
data of the study patients in order to determine each
patient’s correct disease severity on each day. For the
present analysis the latest sepsis-3 definitions of 2016
(i.e. sepsis, septic shock) were applied and all patients
were re-classified according to these new definitions [3].
A minor number of patients had to be down classified,
as in retrospect; they did not fulfill the criteria for sepsis
nor septic shock on day 1 (n = 17). They were therefore
additionally merged with the 60 controls. Naturally, over
the course of ICU treatment, patients improved or dete-
riorated. This means a number of patients, initially pre-
senting with septic shock, could improve to sepsis or
even better between days 3 and 8, while patients with
sepsis on day 1 could develop a septic shock on day 3 or
8. Therefore, on days 3 and 8 the distribution of patients
per group is different than on day 1.
The criteria for sepsis and septic shock were as follows
[3]: Patients were assigned to the sepsis-group if an
increase of the Sequential Organ Failure Assessment
(SOFA) score of 2 points or more was observed as a
consequence to a present infection. When patients
additionally had a persisting hypotension with vasopres-
sor requirement to maintain a mean arterial pressure of
at least 65 mmHg and the serum lactate level was
greater than 2 mmol/l despite volume resuscitation, they
were classified as septic shock.
In the formerly established criteria, there was an
additional definition for severe sepsis, which is now met
by the new criteria for sepsis, as well as for the systemic
inflammatory response syndrome (SIRS), which was diag-
nosed if at least two of the following symptoms were
present: body temperature ≥ 38 °C or ≤36 °C, heart
rate ≥ 90 beats per minute, tachypnea (respiratory
rate ≥ 20/min or hyperventilation: PaCO2 ≤ 32 mmHg)
and leukocytosis (≥12,000/cu mm) or leukopenia
(≤4000/cu mm) [33].
According to new guidelines, lactate levels were assessed
for all patient groups [3, 34]. Disease severity on the ICU
was documented by the acute physiology and chronic
health evaluation II (APACHE II) and the sequential organ
failure assessment (SOFA) score [35, 36].
All patient data, such as creatinine levels, hemoglobin,
hematocrit, white blood cell count, platelet count, CRP,
bilirubin, sodium, potassium, urea, interleukin 6 (IL-6),
PCT, body temperature, respiratory rate, heart rate,
blood pressure, partial pressure of O2 and CO2, bicar-
bonate, base excess, lactate, pH value, Glasgow coma
scale (GCS) were documented from the patient files.
Additionally, prior medical history, age, sex, body weight
and the germ spectrum were documented.
Blood samples for PTX-3 measurements were taken
within 24 h after clinical onset of sepsis or septic shock
on the ICU (day 1) as well as on day 3 and 8 of ICU
treatment. All patients were followed up until 30 days
and 6 months after study inclusion by direct telephone
visits with the patients or their general practitioners.
The main prognostic outcome was all-cause mortality
after 30 days and 6 months.
Biomarker measurements
Blood samples were obtained by venipuncture into
serum and ethylenediaminetetraacetic acid (EDTA)
monovettes® (SARSTEDT AG & Co.; Nümbrecht,
Germany). Within 30 min all blood samples were centri-
fuged at 2500×g at 20 °C for 10 min. Plasma and serum
were separated and aliquoted. The aliquoted samples
were cooled down with liquid nitrogen before being
stored at -80 °C until Analysis.
PTX-3 measurements were performed with the Quan-
tikine® Human Pentraxin 3/TSG-14 Immunoassay (R&D
Systems Inc., Minneapolis, USA) using plasma from
EDTA monovettes®. IL-6 and PCT were measured in
serum. IL-6 was measured with reagents from Roche
Diagnostics (Roche Diagnostics, Mannheim, Germany)
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and PCT was measured with reagents from Thermo
Fisher Scientific (Thermo Fisher Scientific Clinical Diag-
nostics, BRAHMS GmbH, Henningsdorf, Germany). The
assays were performed on a Cobas e601 twin module
and on a Cobas e602 module (Roche Diagnostics, Mann-
heim, Germany). Interleukin-6 and PCT measurements
were performed at the central laboratory in Nuremberg,
Germany.
Statistical analysis
Statistical analysis was performed with InStat (GraphPad
Software) and SPSS software (SPSS Software GmbH).
Comparisons between two groups, for instance healthy
subjects and patients with sepsis, were performed with
the Student’s t-test. In case of more than two groups,
metric variables were compared by analysis of variance
(ANOVA), if applicable. For normally distributed metric
data (as tested by the Kolmogorov-Smirnov test), the
Student t-test was applied. For variables not normally
distributed, the Mann–Whitney U-test was used as a
nonparametric test. Spearman’s rank correlation for non-
parametric data was used to test the association of PTX-
3 blood levels with medical parameters. Qualitative
parameters were analyzed by use of a 2 × 2 contingency
table and Chi2 test or Fisher’s exact test as appropriate.
Quantitative data are presented as mean ± standard
error of mean (SEM) or as median and interquartile
ranges (IQR) (i.e. 25th to 75th percentiles), depending
Table 1 Baseline characteristics of the Mannheim Sepsis Study (MaSep) at day 1
Controls
(n = 77)
Sepsis
(n = 73)
Septic Shock
(n = 140)
p-values
Age, years (mean, range) 64 (42–87) 65 (26–88) 67 (39–87) 0.9
Gender, n (%)
Male 42 (55) 47 (64) 101 (72) <0.001
Female 35 (45) 26 (36) 39 (28) 0.1
Site of infection, n (%)
Lung - 47 (64) 84 (60) 0.001
Urinary tract - 9 (12) 12 (8) 0.5
Abdominal - 10 (14) 15 (11) 0.3
Central nervous system - 0 (0) 0 (0) -
Skin - 2 (3) 8 (6) 0.06
Heart - 4 (6) 4 (3) 1.0
Blood - 1 (1) 10 (7) 0.007
Others - 0 (0) 7 (5) -
Laboratory values, mean ± SEM
White blood cells (109/L) - 16.1 ± 1.4 18.1 ± 1.2 0.4
Platelets, (10E9/L) - 221 ± 16.2 169 ± 9.9 0.01
Bilirubin, mg/dl - 1.6 ± 0.4 3 ± 0.6 0.004
Lactate mg/dl - 2.3 ± 0.2 3.5 ± 0.3 0.002
Creatinine, mg/dl - 2.4 ± 0.2 2.8 ± 0.2 0.05
C reactive proteine, mg/l - 186 ± 12.5 207 ± 9.5 0.2
Procalcitonin, ng/ml - 12.5 ± 2.7 31 ± 5.7 0.002
Interleukin 6, pg/ml - 16,281 ± 15,560 6802 ± 1911 <0.001
pCO2 (mmHg) - 37.9 ± 1.6 43.7 ± 1.6 0.02
Positive blood cultures, n (%) - 28 (38) 62 (44) <0.001
ICU parameters, mean ± SEM
ICU days - 10 ± 1.1 14.6 ± 1.3 0.1
Ventilation days - 4.3 ± 0.9 9.4 ± 1.1 <0.001
Catecholamine days - 2 ± 0.5 7.4 ± 0.6 <0.001
Renal replacement therapy days - 1 ± 0.3 4.2 ± 0.7 <0.001
APACHE II, mean ± SEM - 20.5 ± 0.9 27.6 ± 0.6 <0.001
SOFA score, mean ± SEM - 7.2 ± 0.4 12.3 ± 0.3 <0.001
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on the distribution of the data. For qualitative parame-
ters absolute and relative frequencies are presented. A
test for linear trend was applied to compare the
biomarker levels in the different groups of disease sever-
ity. All analyses were exploratory and a two-tailed
p-value of < 0.05 was taken as a cut-off for statistical
significance.
Diagnostic value of biomarkers
For C-statistics: To evaluate pre-test discriminative
capacities of each biomarker, receiver-operating charac-
teristic (ROC) curve analyses were performed with cal-
culation of area under the curve (AUC) for diagnosis of
sepsis and septic shock during the first week of ICU
treatment at days 1, 3 and 8 for each biomarker. For
PTX-3, diagnostic goodness criteria (that is, accuracy,
specificity, sensitivity, negative/positive predictive values
(NPV/PPV), and relative risk) were calculated. Accuracy
was defined as the sum of true positives plus true nega-
tives divided by all measured patients.
Results
Baseline characteristics are presented in Table 1. A total
of 213 patients and 77 healthy controls have been
enrolled into the MaSep study. At the time of enroll-
ment, 34% of patients suffered from sepsis and 66%
from septic shock, respectively. The most common
Fig. 1 PTX-3 (top), procalcitonin (PCT, middle) and IL-6 plasma levels (bottom) in patients admitted to an internal ICU with proven criteria of sepsis
and septic shock. Left diagrams show results of biomarker measurements at day 1, middle diagrams show results at day 3 and right diagrams show results
at day 8. Seventy-seven individuals served as a control group at day 1. Data are presented as medians with 25th and 75th percentiles (boxes) and 5th and
95th percentiles (whiskers)
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site of infection were the lungs (approximately 62%)
and abdomen (12%).
Distribution of PTX-3 according to latest sepsis-3
definitions
Figure 1 shows the distribution of PTX-3, IL-6 and PCT
in the different groups of disease severity on day 1, 3
and 8. On each day of measurement, PTX-3 levels of
patients with sepsis as well as levels of patients with
septic shock were significantly higher than in the control
group (p ≤ 0.001). Although overall PTX-3 levels showed
a decreasing linear trend from day 1 to day 8 of ICU
treatment (p = 0.0001), median serum PTX-3 levels in
patients with septic shock consistently remained higher
than in patients with sepsis throughout the first week of
ICU treatment.
Within the control cohort, 17 individuals fulfilled the
former criteria for SIRS on day 1 (nd3 = 25, nd8 = 36).
Figure 2 demonstrates the PTX-3 levels in this cohort
compared to patients with sepsis. PTX-3 levels on day
one were higher in the sepsis cohort (median 31.4 ng/ml)
compared to the SIRS cohort (median 23.8 ng/ml),
however not statistically significant (p > 0.05). Accord-
ingly, no significant difference was shown on days 3 and 8
between both subgroups.
Univariate correlations of PTX-3 levels
Statistically significant correlations of PTX-3-levels were
shown with the following clinical parameters (Table 2):
higher lactate levels (r = 0.36, p < 0.0001), APACHE II
score (r = 0.36, p < 0.0001), a higher SOFA score
(r = 0.36, p < 0.0001) as well as with a lower mean
arterial pressure (r = −0.25, p < 0.0001) and higher
serum creatinine (r = 0.17, p < 0.01). There was also a
significant association of PTX-3 with the established
inflammatory biomarkers IL-6 (r = 0.37, p < 0.0001), PCT
(r = 0.28, p < 0.0001), and CRP (r = 0.26, p < 0.0001).
PTX-3 discriminates sepsis and septic shock according to
latest sepsis-3 definitions
C-statistics revealed valuable diagnostic capacity for
PTX-3 (Table 3). Diagnostic AUCs for discriminating
patients with at least sepsis were statistically significant
on each day of measurement (p = 0.0001) (Fig. 3a).
PTX-3 levels valuably discriminated the presence of at
least sepsis on each day (minimal AUC = 0.82) (Fig. 3a)
as well as of septic shock (minimal AUC = 0.73)
(Fig. 3b) and was overall comparable to IL-6 and
PCT (Table 3).
In addition, CRP also showed statistically significant
AUCs to discriminate sepsis and septic shock on each
day. However the AUCs of CRP were consistently lower
than those of PTX-3 throughout the first week of ICU
treatment. The white blood cell count was not able to
discriminate sepsis or septic shock on day 1 or 3 and
revealed only moderate diagnostic value on day 8 with
AUCs below 0.75 (Table 3).
Subsequently, uniform diagnostic cut-offs were defined
to diagnose at least sepsis (≥5.0 ng/ml) and septic shock
(≥9.0 ng/ml) (Table 4), while trying to maintain a sensi-
tivity of at least 70% on each day of measurement, with
focus on the first day to enable an early diagnosis.
Specifically for the presence of sepsis, the minimal sensi-
tivity was 92% with an according negative predictive
value of at least 89%, throughout all treatment days 1,
3 and 8.
Discussion
The present study evaluates the diagnostic value of
PTX-3 in patients with sepsis and septic shock according
to the latest Sepsis-3 definitions during the first week of
intensive care treatment. Since sepsis and septic shock
are usually diagnosed inadequately and delayed, current
guidelines still demand time-dependent risk stratification
of each individual patient during intensive care treat-
ment. Accordingly, diagnostic assessment of study
Fig. 2 PTX-3 levels in patients admitted to an internal ICU with proven criteria of SIRS and sepsis on day 1 (left), 3 (middle) and 8 (right). Data are
presented as medians with 25th and 75th percentiles (boxes) and 5th and 95th percentiles (whiskers)
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patients was performed exemplarily on day 1, 3 and 8 of
ICU treatment.
The study revealed that valuable and consistent dis-
crimination of sepsis and septic shock was achieved by
measurements of PTX-3 plasma levels during days 1, 3,
and 8 of ICU treatment, specifically for the presence of
at least sepsis. In addition, PTX-3 correlated with disease
severity and degree of organ dysfunctions as assessed by
clinical scores such as the SOFA score, as has also been
described in earlier studies [24, 31]. In line with previous
studies, this study confirms that circulating PTX3 con-
centrations are elevated in sepsis and even higher in sep-
tic shock [31]. Consistent with the current observations,
multiple previous studies presented significant and valu-
able AUCs for discriminating sepsis or septic shock from
healthy controls [24, 28, 29]. The diagnostic superiority
of PTX-3 over PCT or CRP is still under debate, as dif-
ferent studies so far have been inconsistent regarding
their diagnostic capacity in patients with sepsis and sep-
tic shock, applying different criteria and definitions of
the sepsis syndrome [24, 28]. No study is currently avail-
able applying the newest Sepsis-3 definitions for novel
biomarker analyses.
In contrast to previous studies, the present one
aimed to evaluate the potential diagnostic value of
PTX-3 in a real-life setting during the first week of
treatment on a medical ICU, representing the most
critical time frame of patients suffering from sepsis
or septic shock [5, 6, 37]. Combining PTX-3 with
established biomarkers, such as IL-6, might be of
additional value for the discrimination of sepsis and
septic shock. Notably, the presented detailed correla-
tions and comparisons of PTX-3 with other estab-
lished clinical parameters have only scarcely been
described yet [31]. The ongoing systemic activation
of inflammatory biomarkers such as CRP,
interleukin-6 and PCT during sepsis and septic
shock may be an explanation of their correlation
with PTX-3 levels in affected patients [38, 39]. PTX-
3 itself is known to be induced by several cytokines
Table 2 Univariate correlations of PTX-3 with laboratory and clinical
parameters in all patients (n=213) at day 1
r p value
Creatinine 0.17 0.013
Bilirubin 0.22 0.003
Lactate 0.36 <0.001
Platelets −0.19 0.005
C reactive proteine (CRP) 0.26 <0.001
Procalcitonin (PCT) 0.28 <0.001
Interleukin 6 0.37 <0.001
Mean arterial pressure −0.25 <0.001
Mechanical ventilation days 0.17 0.011
Catecholamines days 0.18 0.009
SAPS II score 0.27 <0.001
APACHE II score 0.36 <0.001
SOFA score 0.36 <0.001
Table 3 Discriminative capacitites of biomarkers for diagnosis of sepsis severity at days 1, 3 and 8 of ICU treatment, analyzed as area
under the curves (AUCs (95% CI))
Pentraxin-3 Interleukin-6 Procalcitonin CRP White blood cells
Day 1
≥ Sepsis
(n = 213)
0.92 (0.87–0.97)
p = 0.0001
0.91 (0.86–0.95)
p = 0.0001
0.92 (0.88–0.97)
p = 0.0001
0.82 (0.72–0.91)
p = 0.0001
0.59 (0.46–0.72)
p = 0.2
Septic shock
(n = 140)
0.81 (0.77–0.86)
p = 0.0001
0.81 (0.76–0.85)
p = 0.0001
0.79 (0.74–0.84)
p = 0.0001
0.61 (0.53–0.68)
p = 0.008
0.55 (0.47–0.62)
p = 0.2
Day 1: controls n = 77; sepsis n = 73; septic shock n = 140.
Day 3
≥ Sepsis
(n = 154)
0.84 (0.79–0.90)
p = 0.0001
0.84 (0.78–0.89)
p = 0.0001
0.84 (0.78–0.90)
p = 0.0001
0.70 (0.60–0.79)
p = 0.0001
0.53 (0.42–0.63)
p = 0.6
Septic shock
(n = 80)
0.73 (0.67–0.80)
p = 0.0001
0.79 (0.73–0.85)
p = 0.0001
0.74 (0.68–0.80)
p = 0.0001
0.69 (0.61–0.76)
p = 0.001
0.54 (0.46–0.63)
p = 0.3
Day 3: controls n = 99; sepsis n = 74; septic shock n = 80.
Day 8
≥ Sepsis
(n = 80)
0.82 (0.77–0.88)
p = 0.0001
0.83 (0.77–0.88)
p = 0.0001
0.79 (0.74–0.85)
p = 0.0001
0.74 (0.66–0.82)
p = 0.0001
0.66 (0.57–0.75)
p = 0.001
Septic shock
(n = 39)
0.79 (0.72–0.85)
p = 0.0001
0.81 (0.75–0.88)
p = 0.0001
0.81 (0.75–0.87)
p = 0.0001
0.70 (0.60–0.79)
p = 0.0001
0.74 (0.65–0.83)
p = 0.0001
Day 8: controls n = 143; sepsis n = 41; septic shock n = 39.
A minimal AUC was set at ≥0.75 (highlighted in bold type). Significant p values (<0.05) are in italic type
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leading to a rapid synthesis in-vitro [11, 12]. Specif-
ically the stimulation by interleukin-1 and TNF-α
was shown to increase plasma levels of PTX-3. This
effect was shown in various cells and inflammatory
steps, such as during the initial phase of inflamma-
tion by recognizing pathogens and activation of the
complement pathway, thus allowing an approach to
explain the early elevated PTX-3 plasma levels in
patients with infection [11, 12, 23].
PTX-3 levels revealed no significant difference
between patients with SIRS and sepsis in the present co-
hort. Previous studies measured PTX-3 levels in both
Fig. 3 Receiver-operating characteristic (ROC) curves revealing valuable discrimination of patients with sepsis (a) and septic shock (b) by serum
levels of PTX-3, IL-6 and PCT on day 1, 3 and 8 (from top to bottom)
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groups, however did not compare the values for statis-
tical significance [24]. Additionally it should be noted,
that SIRS is considered inadequately specific and sensi-
tive and is no longer part of the sepsis definitions [3].
The strengths of the present study were its pro-
spective character, augmenting the current knowledge
about PTX-3 by evaluating its diagnostic capacity at
different time points of the first week of ICU treat-
ment. Additionally, this study provides the first
analysis of PTX-3 within the individual subgroups
sepsis and septic shock as classified by implementing
the recently updated sepsis-3 definitions [3]. It is
important to identify these high risk patients as they
are endangered of fatal outcome even within the
following months after hospital discharge [38]. Novel
biomarkers such as PTX-3 in combination with estab-
lished ones such as IL-6 might improve the individual
time-dependent risk-stratification of patients with
sepsis or septic shock.
Limitations
The present study was performed as a single centre
study. Analyses were not blinded to white blood cells
and CRP, as both are used in daily routine by the prac-
ticing clinicians. After retrospective re-evaluation of
main diagnoses, a minor part of the patients was down-
graded to controls. Only patients with an infection and
an increase in SOFA Score were included in the study,
not allowing a statement on the differentiation between
an infection without increase in SOFA score and pa-
tients with sepsis. Upcoming randomised controlled
multi-centre studies might verify the results of the
present study.
Conclusions
In summary, PTX-3 valuably discriminates the differ-
ent stages of sepsis severity during the first week of
intensive care treatment according to latest Sepsis-3
definitions.
Key points
 PTX-3 was evaluated in 213 medical ICU patients
suspected to suffer from at least sepsis.
 PTX-3 discriminates valuably sepsis and septic
shock from healthy controls corresponding to
uniform cutoff levels.
 PTX-3 was evaluated according to the latest Sepsis-3
definitions.
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